---
document_datetime: 2025-12-29 07:33:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/paxneury.html
document_name: paxneury.html
version: success
processing_time: 0.0995532
conversion_datetime: 2025-12-31 03:25:46.906285
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Paxneury

[RSS](/en/individual-human-medicine.xml/253184)

##### Authorised

This medicine is authorised for use in the European Union

guanfacine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Paxneury](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Paxneury is used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years when stimulant medicines are not appropriate or do not control their symptoms well enough.

Paxneury is used as part of a comprehensive treatment programme that typically involves psychological, educational and other interventions.

Paxneury contains the active substance guanfacine and is a 'hybrid' and a 'generic' medicine. This means that it is similar to a 'reference medicine' containing the same active substance, but there are certain differences between the two. The reference medicine for Paxneury is Intuniv. Paxneury is available in the same strengths as Intuniv (1, 2, 3 and 4 mg) as well as in the additional strengths 4,5 and 7 mg.

Expand section

Collapse section

## How is Paxneury used?

Paxneury treatment must be started by a doctor specialised in childhood or adolescent behavioural problems. Before starting treatment, the doctor should carry out checks to see whether the patient is at risk of side effects of the medicine (particularly sleepiness, effects on heart rate and blood pressure, and weight gain).

The dose of Paxneury requires careful adjustments, taking into account side effects and benefits seen in the patient. Weekly monitoring for signs and symptoms of sleepiness and effects on heart rate and blood pressure is required at the start of treatment and the patient should continue to be monitored at least every 3 months for the first year. Six-monthly monitoring is required thereafter, with more frequent monitoring following any dose adjustment.

The recommended starting dose for all patients is 1 mg taken by mouth once a day which is increased to a maintenance dose based on body weight according to the patient's response and tolerability. The medicine can only be obtained with a prescription.

For more information about using Paxneury, see the package leaflet or contact your doctor or pharmacist.

## How does Paxneury work?

The way Paxneury works in ADHD is not established. It is thought that the active substance, guanfacine, might influence the way signals are transmitted between cells in areas of the brain called the prefrontal cortex and basal ganglia by attaching to certain receptors that are heavily concentrated in these areas.

## How has Paxneury been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Intuniv, and do not need to be repeated for Paxneury.

As for every medicine, the company provided studies on the quality of Paxneury. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Paxneury?

Because Paxneury is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Paxneury authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Paxneury has been shown to have comparable quality and to be bioequivalent to the reference medicine. Therefore, the Agency's view was that, as for the reference medicine, the benefits of Paxneury outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Paxneury?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Paxneury have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for reference medicine also apply to Paxneury where appropriate.

As for all medicines, data on the use of Paxneury are continuously monitored. Suspected side effects reported with Paxneury are carefully evaluated and any necessary action taken to protect patients.

## Other information about Paxneury

Paxneury received a marketing authorisation valid throughout the EU on 26 February 2025.

Paxneury : EPAR - Medicine overview

Reference Number: EMA/39565/2025

English (EN) (165.02 KB - PDF)

**First published:** 11/03/2025

[View](/en/documents/overview/paxneury-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-561)

български (BG) (190.22 KB - PDF)

**First published:**

11/03/2025

[View](/bg/documents/overview/paxneury-epar-medicine-overview_bg.pdf)

español (ES) (164.79 KB - PDF)

**First published:**

11/03/2025

[View](/es/documents/overview/paxneury-epar-medicine-overview_es.pdf)

čeština (CS) (187.11 KB - PDF)

**First published:**

11/03/2025

[View](/cs/documents/overview/paxneury-epar-medicine-overview_cs.pdf)

dansk (DA) (165.22 KB - PDF)

**First published:**

11/03/2025

[View](/da/documents/overview/paxneury-epar-medicine-overview_da.pdf)

Deutsch (DE) (168.95 KB - PDF)

**First published:**

11/03/2025

[View](/de/documents/overview/paxneury-epar-medicine-overview_de.pdf)

eesti keel (ET) (162.71 KB - PDF)

**First published:**

11/03/2025

[View](/et/documents/overview/paxneury-epar-medicine-overview_et.pdf)

ελληνικά (EL) (188.54 KB - PDF)

**First published:**

11/03/2025

[View](/el/documents/overview/paxneury-epar-medicine-overview_el.pdf)

français (FR) (166.63 KB - PDF)

**First published:**

11/03/2025

[View](/fr/documents/overview/paxneury-epar-medicine-overview_fr.pdf)

hrvatski (HR) (185 KB - PDF)

**First published:**

11/03/2025

[View](/hr/documents/overview/paxneury-epar-medicine-overview_hr.pdf)

italiano (IT) (163.22 KB - PDF)

**First published:**

11/03/2025

[View](/it/documents/overview/paxneury-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (200.98 KB - PDF)

**First published:**

11/03/2025

[View](/lv/documents/overview/paxneury-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (185.41 KB - PDF)

**First published:**

11/03/2025

[View](/lt/documents/overview/paxneury-epar-medicine-overview_lt.pdf)

magyar (HU) (186.97 KB - PDF)

**First published:**

11/03/2025

[View](/hu/documents/overview/paxneury-epar-medicine-overview_hu.pdf)

Malti (MT) (187.65 KB - PDF)

**First published:**

11/03/2025

[View](/mt/documents/overview/paxneury-epar-medicine-overview_mt.pdf)

Nederlands (NL) (166.29 KB - PDF)

**First published:**

11/03/2025

[View](/nl/documents/overview/paxneury-epar-medicine-overview_nl.pdf)

polski (PL) (190.04 KB - PDF)

**First published:**

11/03/2025

[View](/pl/documents/overview/paxneury-epar-medicine-overview_pl.pdf)

português (PT) (166.01 KB - PDF)

**First published:**

11/03/2025

[View](/pt/documents/overview/paxneury-epar-medicine-overview_pt.pdf)

română (RO) (181.04 KB - PDF)

**First published:**

11/03/2025

[View](/ro/documents/overview/paxneury-epar-medicine-overview_ro.pdf)

slovenčina (SK) (185.69 KB - PDF)

**First published:**

11/03/2025

[View](/sk/documents/overview/paxneury-epar-medicine-overview_sk.pdf)

slovenščina (SL) (173.41 KB - PDF)

**First published:**

11/03/2025

[View](/sl/documents/overview/paxneury-epar-medicine-overview_sl.pdf)

Suomi (FI) (162.44 KB - PDF)

**First published:**

11/03/2025

[View](/fi/documents/overview/paxneury-epar-medicine-overview_fi.pdf)

svenska (SV) (162.9 KB - PDF)

**First published:**

11/03/2025

[View](/sv/documents/overview/paxneury-epar-medicine-overview_sv.pdf)

Paxneury : EPAR - Risk management plan

English (EN) (347.62 KB - PDF)

**First published:** 11/03/2025

[View](/en/documents/rmp/paxneury-epar-risk-management-plan_en.pdf)

## Product information

Paxneury : EPAR - Product information

English (EN) (647.4 KB - PDF)

**First published:** 11/03/2025

[View](/en/documents/product-information/paxneury-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-920)

български (BG) (610.15 KB - PDF)

**First published:**

11/03/2025

[View](/bg/documents/product-information/paxneury-epar-product-information_bg.pdf)

español (ES) (498.17 KB - PDF)

**First published:**

11/03/2025

[View](/es/documents/product-information/paxneury-epar-product-information_es.pdf)

čeština (CS) (574.74 KB - PDF)

**First published:**

11/03/2025

[View](/cs/documents/product-information/paxneury-epar-product-information_cs.pdf)

dansk (DA) (466.23 KB - PDF)

**First published:**

11/03/2025

[View](/da/documents/product-information/paxneury-epar-product-information_da.pdf)

Deutsch (DE) (507.17 KB - PDF)

**First published:**

11/03/2025

[View](/de/documents/product-information/paxneury-epar-product-information_de.pdf)

eesti keel (ET) (471.53 KB - PDF)

**First published:**

11/03/2025

[View](/et/documents/product-information/paxneury-epar-product-information_et.pdf)

ελληνικά (EL) (655.81 KB - PDF)

**First published:**

11/03/2025

[View](/el/documents/product-information/paxneury-epar-product-information_el.pdf)

français (FR) (510.95 KB - PDF)

**First published:**

11/03/2025

[View](/fr/documents/product-information/paxneury-epar-product-information_fr.pdf)

hrvatski (HR) (551.17 KB - PDF)

**First published:**

11/03/2025

[View](/hr/documents/product-information/paxneury-epar-product-information_hr.pdf)

íslenska (IS) (493.26 KB - PDF)

**First published:**

11/03/2025

[View](/is/documents/product-information/paxneury-epar-product-information_is.pdf)

italiano (IT) (506.03 KB - PDF)

**First published:**

11/03/2025

[View](/it/documents/product-information/paxneury-epar-product-information_it.pdf)

latviešu valoda (LV) (569.3 KB - PDF)

**First published:**

11/03/2025

[View](/lv/documents/product-information/paxneury-epar-product-information_lv.pdf)

lietuvių kalba (LT) (583.6 KB - PDF)

**First published:**

11/03/2025

[View](/lt/documents/product-information/paxneury-epar-product-information_lt.pdf)

magyar (HU) (576.2 KB - PDF)

**First published:**

11/03/2025

[View](/hu/documents/product-information/paxneury-epar-product-information_hu.pdf)

Malti (MT) (587.47 KB - PDF)

**First published:**

11/03/2025

[View](/mt/documents/product-information/paxneury-epar-product-information_mt.pdf)

Nederlands (NL) (477.33 KB - PDF)

**First published:**

11/03/2025

[View](/nl/documents/product-information/paxneury-epar-product-information_nl.pdf)

norsk (NO) (452.18 KB - PDF)

**First published:**

11/03/2025

[View](/no/documents/product-information/paxneury-epar-product-information_no.pdf)

polski (PL) (600.93 KB - PDF)

**First published:**

11/03/2025

[View](/pl/documents/product-information/paxneury-epar-product-information_pl.pdf)

português (PT) (495.74 KB - PDF)

**First published:**

11/03/2025

[View](/pt/documents/product-information/paxneury-epar-product-information_pt.pdf)

română (RO) (575.75 KB - PDF)

**First published:**

11/03/2025

[View](/ro/documents/product-information/paxneury-epar-product-information_ro.pdf)

slovenčina (SK) (547.72 KB - PDF)

**First published:**

11/03/2025

[View](/sk/documents/product-information/paxneury-epar-product-information_sk.pdf)

slovenščina (SL) (568.06 KB - PDF)

**First published:**

11/03/2025

[View](/sl/documents/product-information/paxneury-epar-product-information_sl.pdf)

Suomi (FI) (778.71 KB - PDF)

**First published:**

11/03/2025

[View](/fi/documents/product-information/paxneury-epar-product-information_fi.pdf)

svenska (SV) (978.64 KB - PDF)

**First published:**

11/03/2025

[View](/sv/documents/product-information/paxneury-epar-product-information_sv.pdf)

26/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Paxneury : EPAR - All authorised presentations

English (EN) (35.38 KB - PDF)

**First published:** 11/03/2025

[View](/en/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-253)

български (BG) (37.88 KB - PDF)

**First published:**

11/03/2025

[View](/bg/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_bg.pdf)

español (ES) (35.26 KB - PDF)

**First published:**

11/03/2025

[View](/es/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.6 KB - PDF)

**First published:**

11/03/2025

[View](/cs/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (36.31 KB - PDF)

**First published:**

11/03/2025

[View](/da/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.32 KB - PDF)

**First published:**

11/03/2025

[View](/de/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35.91 KB - PDF)

**First published:**

11/03/2025

[View](/et/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.78 KB - PDF)

**First published:**

11/03/2025

[View](/el/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_el.pdf)

français (FR) (59.04 KB - PDF)

**First published:**

11/03/2025

[View](/fr/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36 KB - PDF)

**First published:**

11/03/2025

[View](/hr/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (35.76 KB - PDF)

**First published:**

11/03/2025

[View](/is/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34.29 KB - PDF)

**First published:**

11/03/2025

[View](/it/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.02 KB - PDF)

**First published:**

11/03/2025

[View](/lv/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.7 KB - PDF)

**First published:**

11/03/2025

[View](/lt/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.72 KB - PDF)

**First published:**

11/03/2025

[View](/hu/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (36.78 KB - PDF)

**First published:**

11/03/2025

[View](/mt/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (36.23 KB - PDF)

**First published:**

11/03/2025

[View](/nl/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (35.65 KB - PDF)

**First published:**

11/03/2025

[View](/no/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.16 KB - PDF)

**First published:**

11/03/2025

[View](/pl/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.94 KB - PDF)

**First published:**

11/03/2025

[View](/pt/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.66 KB - PDF)

**First published:**

11/03/2025

[View](/ro/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.9 KB - PDF)

**First published:**

11/03/2025

[View](/sk/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (36.25 KB - PDF)

**First published:**

11/03/2025

[View](/sl/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (34.55 KB - PDF)

**First published:**

11/03/2025

[View](/fi/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.95 KB - PDF)

**First published:**

11/03/2025

[View](/sv/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Paxneury Active substance guanfacine hydrochloride International non-proprietary name (INN) or common name guanfacine Therapeutic area (MeSH) Attention Deficit Disorder with Hyperactivity Anatomical therapeutic chemical (ATC) code C02AC02

### Pharmacotherapeutic group

Antihypertensives

### Therapeutic indication

Paxneury is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.

Paxneury must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.

## Authorisation details

EMA product number EMEA/H/C/006312

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Neuraxpharm Pharmaceuticals S.L.

Avinguda De Barcelona 69 Poligono Industrialde La Fuensanta 08970 Sant Joan Despi SPAIN

Opinion adopted 12/12/2024 Marketing authorisation issued 26/02/2025

## Assessment history

## Initial marketing authorisation documents

Paxneury : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/14178/2025

English (EN) (4.07 MB - PDF)

**First published:** 11/03/2025

[View](/en/documents/assessment-report/paxneury-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Paxneury

Adopted

Reference Number: EMA/CHMP/575645/2024

English (EN) (145.06 KB - PDF)

**First published:** 13/12/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-paxneury_en.pdf)

#### News on Paxneury

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

**This page was last updated on** 11/03/2025

## Share this page

[Back to top](#main-content)